Skip to main content

Abstract

Objective:

Alcohol use disorders are common conditions that have enormous social and economic consequences. Genome-wide association analyses were performed to identify genetic variants associated with a proxy measure of alcohol consumption and alcohol misuse and to explore the shared genetic basis between these measures and other substance use, psychiatric, and behavioral traits.

Method:

This study used quantitative measures from the Alcohol Use Disorders Identification Test (AUDIT) from two population-based cohorts of European ancestry (UK Biobank [N=121,604] and 23andMe [N=20,328]) and performed a genome-wide association study (GWAS) meta-analysis. Two additional GWAS analyses were performed, a GWAS for AUDIT scores on items 1–3, which focus on consumption (AUDIT-C), and for scores on items 4–10, which focus on the problematic consequences of drinking (AUDIT-P).

Results:

The GWAS meta-analysis of AUDIT total score identified 10 associated risk loci. Novel associations localized to genes including JCAD and SLC39A13; this study also replicated previously identified signals in the genes ADH1B, ADH1C, KLB, and GCKR. The dimensions of AUDIT showed positive genetic correlations with alcohol consumption (rg=0.76–0.92) and DSM-IV alcohol dependence (rg=0.33–0.63). AUDIT-P and AUDIT-C scores showed significantly different patterns of association across a number of traits, including psychiatric disorders. AUDIT-P score was significantly positively genetically correlated with schizophrenia (rg=0.22), major depressive disorder (rg=0.26), and attention deficit hyperactivity disorder (rg=0.23), whereas AUDIT-C score was significantly negatively genetically correlated with major depressive disorder (rg=−0.24) and ADHD (rg=−0.10). This study also used the AUDIT data in the UK Biobank to identify thresholds for dichotomizing AUDIT total score that optimize genetic correlations with DSM-IV alcohol dependence. Coding individuals with AUDIT total scores ≤4 as control subjects and those with scores ≥12 as case subjects produced a significant high genetic correlation with DSM-IV alcohol dependence (rg=0.82) while retaining most subjects.

Conclusions:

AUDIT scores ascertained in population-based cohorts can be used to explore the genetic basis of both alcohol consumption and alcohol use disorders.

Formats available

You can view the full content in the following formats:

Supplementary Material

File (appi.ajp.2018.18040369.ds001.pdf)
File (appi.ajp.2018.18040369.ds002.xlsx)
File (appi.ajp.2018.18040369.ds002_tables.xlsx)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 107 - 118
PubMed: 30336701

History

Received: 3 April 2018
Revision received: 18 July 2018
Accepted: 9 August 2018
Published online: 19 October 2018
Published in print: February 01, 2019

Keywords

  1. Alcohol Abuse
  2. Genetics
  3. Epidemiology
  4. Alcohol Consumption
  5. Genome-Wide Association Studies
  6. Alcohol Dependence

Authors

Affiliations

Sandra Sanchez-Roige, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Abraham A. Palmer, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Pierre Fontanillas, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Sarah L. Elson, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
the 23andMe Research Team, the Substance Use Disorder Working Group of the Psychiatric Genomics Consortium
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Mark J. Adams, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
David M. Howard, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Howard J. Edenberg, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Gail Davies, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Richard C. Crist, Ph.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Ian J. Deary, Ph.D., M.R.C.Psych.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Andrew M. McIntosh, M.D.
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Toni-Kim Clarke, Ph.D. [email protected]
From the Department of Psychiatry and the Institute for Genomic Medicine, University of California San Diego, La Jolla; 23andMe, Inc., Mountain View, Calif.; the Division of Psychiatry, the Department of Psychology, and the Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, U.K.; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; and the Translational Research Laboratories, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.

Notes

Address correspondence to Dr. Clarke ([email protected]).

Competing Interests

Drs. Fontanillas and Elson and the members of the 23andMe Research Team are employees of 23andMe. Dr. McIntosh has received research support from Eli Lilly, Janssen, Pfizer, and the Sackler Foundation. The other authors report no financial relationships with commercial interests.

Funding Information

Frontiers of Innovation Scholars Program: #3-P3029
Medical Research Council10.13039/501100000265: MR/K026992/1
Pilot Award: DA037844
Interdisciplinary Research Fellowship in NeuroAIDS: MH081482
Wellcome Trust10.13039/100004440: 104036/Z/14/Z
Dr. Sanchez-Roige was supported by the Frontiers of Innovation Scholars Program (3-P3029), the Interdisciplinary Research Fellowship in NeuroAIDS (MH081482), and a pilot award from DA037844. This research was conducted using the UK Biobank Resource, application number 4844, and was supported by a Wellcome Trust Strategic Award (Stratifying Resilience and Depression Longitudinally; reference 104036/Z/14/Z) and by the Centre for Cognitive Ageing and Cognitive Epidemiology, which was funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council (reference MR/K026992/1).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share